A new, integrated, continuous purification process template for monoclonal antibodies Alex Xenopoulos* Alison Dupont, Christopher Gillespie, Ajish Potty, Michael Phillips Processing Technologies Merck Millipore Bedford, MA (USA) Integrated Continuous Biomanufacturing A new ECI conference Castelldefels, Spain October 20-24, 2013 Highlights We developed a flow-through purification train that enables an integrated, continuous process We have novel solutions for continuous clarification and capture Bench-scale proof of principle for several mAbs shown Breakthrough improvements not possible unless you look at new technologies 2 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Monoclonal antibody production A mature, robust industry Yet, several issues remain Templated process Protein A chromatography Stability Capital and utilities Large footprint Frequent bottlenecks Sterility Cleaning validation 3 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL New alternative template 2° depth filtration Bioreactor CEX b/e chrom AEX f/t chrom Virus filtration UF/DF Centrifuge 1° depth filtration Bioreactor w/ precipitation Clarification 4 Protein A b/e chrom AX | ECI Castelldefels | 21Oct2013 Protein A b/e chrom continuous Capture Carbon f/t device AEX f/t device CEX f/t device Purification/polishing CONFIDENTIAL Comparison of templates – icons sized by device volume 3.3 m2 14.1 L 14.1 L 19.3 L 0.6 L each 4.4 m2 Clarification 5 AX | ECI Castelldefels | 21Oct2013 5L Capture 0.4 L 3L Purification/polishing 1,000 L @ 2 g/L CONFIDENTIAL Comparison of templates – pool tanks 500 L 1000 L 250 L 50 L Clarification 6 AX | ECI Castelldefels | 21Oct2013 Capture Purification/polishing CONFIDENTIAL Clarification assisted by precipitation and using novel Clarisolve™ filters results in post-Protein A benefits Status Three launched Clarisolve™ filters optimized for particle size Portfolio of flocculants Continuous harvesting and loading of protein A column successful and beneficial Benefits Elimination of centrifuge up to 6,000 L 1000 Increased throughput (<3x membrane area) 900 Depth Filtered DNA removal (1-2 LRV) Advantages persist post protein A Reduced turbidity Enhanced HCP clearance Reduced resin cleaning 7 AX | ECI Castelldefels | 21Oct2013 Turbidity (NTU) 800 700 Smart Polymer 600 500 400 300 200 100 0 4 4.5 5 5.5 pH 6 6.5 7 CONFIDENTIAL Capture with continuous multicolumn chromatography and incompressible Protein A resins offers savings 80 buffer/ resin savings 70 Status time savings DBC @ 1% BT (g/L) 60 Two incompressible resins available Prosep® Ultra Plus Eshmuno® A 50 40 30 20 Two-column continuous One-column batch 10 0 Continuous loading from clarified harvest and continuous loading to purification train successfully shown Benefits Higher productivity, especially at low residence times 0 1.5 2 2.5 3 3.5 RT (min) Effective DBC (g/L) Productivity (g/L/hr) 1-column batch 4 39 1-column batch 0.22 7 7 19 3-column continuous 0.22 37 136 Effective DBC (g/L) RT (min) Consumed resin (L) Consumed buffer (L) Batch 39 4 21 2646 Continuous 45 0.5 2.8 2009 87% 24% Savings AX | ECI Castelldefels | 21Oct2013 1 Residence time (min) Resin and buffer savings 8 0.5 CONFIDENTIAL Protein A capture cannot be beaten as part of a holistic process evaluation Why not CEX chromatography? Why not precipitation? Cheaper resin Cheaper unit operation Single-use Buffer consumption Processing time Two dilution steps – volume increase Longer processing time Higher water/buffer use Lower selectivity Less virus removal Lower yield Increased process development Less templatable More materials Additional unit operations Precipitant removal No product concentration Dilution steps No purification Increased process development More expensive More expensive at commercial scale 9 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Purification in flow-through mode using novel adsorbers, minimum interventions, fewer pool tanks and one skid Traditional Process CEX b/e Low pH VI Pool CEX Pool Proposed Process Carbon + AEX f/t 10 Low pH VI Pool AX | ECI Castelldefels | 21Oct2013 VF with prefiltration AEX f/t AEX Pool VF Pool CEX f/t + VF VF Pool In-line pH CONFIDENTIAL Low MW high Novel flow-through adsorber functionalities work synergistically to remove several classes of impurities Larger acidic HCP, DNA, viruses mAb Aggregates CEX MAb AEX Low MW impurities (leached Protein A, HCP, fragments) Carbon Cell culture components Insulin, methotrexate, Pluronic F68®, hygromycin, antifoam C Process-related impurities DNA, HCP, leached Protein A, viruses Product-related impurities Aggregates, fragments acidic pI basic 11 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Benefits of flow-through purification Disposable chromatography devices connected without pool tanks No bind/elute chromatographic steps Minimal interventions Orthogonal mechanisms for impurity removal Needed pH adjustments incorporated in skid One skid (protein A elution TFF) is possible Enables integrated, continuous process template 12 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Internal bench-scale experimental case studies: Robustness of flow-through purification train (3 mAbs) mAb Monomer Aggregates Yield ProtA VF pool (%) (%) HCP ProA VF pool (ppm) VF Capacity (kg/m2) mAb04 88 N/A 250 2 > 3.5 mAb05 92 5.0 1.0 591 1 >3.6 mAb07 91 1.4 ~0 82 1 >3.7 13 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL External trials: Robustness of flow-through purification train (7 mAbs) # Monomer yield (%) Aggregates (%) Fragments (%) HCP (ppm) 1 91 5.1 0.8 1.2 0.1 688 4 2 83 1.0 <0.1 0.3 0 64 <1 3 87 1.6 0.6 n/a 80 3 4 86 2.0 0.8 0.2 0 350 7 5 84 1.6 0.6 0.13 0 155 <1 6 85 9.2 2.7 n/a 600 6 7 91 3.0 0.8 n/a 1468 7 Loadings of activated carbon and f/t CEX devices were 0.5 – 1.0 kg/L 14 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Internal case studies: Product quality Current process 92% HCP: 11 ppm Leached ProtA: 10 ppm DNA: < 10 ppb Alternative process 87% HCP: 2 ppm Leached ProtA : 4 ppm DNA: < 10 ppb 1/98/1 0.5/99/0.5 15/71/13 13/72/15 Glycan profile (% Gal: 0/1/2) 79/19/2 79/20/2 Higher order structure (CD) No change No change Yield Process-related impurities Product-related impurities (% HMW/Main/LMW) Charge variants (% Acidic/Main/Basic) 15 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Cost of Goods: where is the advantage? labor 5 kL @ 5 g/L commercial consumables 40 labor consumables materials facility 1 kL @ 1 g/L clinical 400 materials facility 4 300 2 15 20 16 DSP cost ($/g) DSP cost ($/g) 30 200 62 39 155 3 91 100 10 3 12 42 65 5 16 37 0 0 Old batch 41 Old batch New continuous New continuous % cost savings for DSP process 5 g/L @ 5,000 L commercial 1 g/L @ 1,000 L clinical Old batch New continuous 24% 35% AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Process modeling: advantages of proposed template Units Current process Alternative process % change Equipment cost $M 6.9 3.1 55% Footprint m2 87 59 32% Water use (incl cleaning) L/g of mAb 24.2 1.4 94% Buffer use (excl WFI) L/g of mAb 2.4 1.0 58% hrs 55 30 45% $/g of mAb 219 109 50% Parameter for DSP portion Processing time Cost 1,000 L @ 2 g/L | 2 kg batch | ~70% yield 17 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Key features of the alternative template An alternative templated process for downstream purification of mAbs is proposed It matches performance of current templates, provides operational advantages Features: • Novel downstream purification process for mAbs – from bioreactor through formulation • Connected unit operations – continuous operation, minimal interventions • Novel unit operations developed – leverage continuous nature • Clarification toolbox – novel depth filters, precipitating agents • Product capture with continuous multicolumn protein A affinity chromatography – efficient use of resin and buffer • Flow-through polishing – no bind/elute steps, improved simplicity and economics • Virus filtration and ultrafiltration/diafiltration – no changes • Proof of concept and feasibility data generated – performance equivalent to current, advantages in overall operational flexibility 18 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL Acknowledgments Downstream Technologies, MM Analytical Technologies, MM • Kevin Galipeau • Rong-Rong Zhu • Meghan Higson • Michael Bruce • Jad Jaber • Mikhail Kozlov Team Supply, MM • Matthew Stone • Michael McGlothlen • William Cataldo • Patricia Kumpey • Romas Skudas • Paul Hatch • Jeff Caron • Jonathan Steen Business Development, MM • Scott Bliss • Fred Mann • Dennis Aquino • Wilson Moya BioPharm Services, Inc • Andrew Brown 19 AX | ECI Castelldefels | 21Oct2013 CONFIDENTIAL CONFIDENTIAL